“Evaluation of the Efficacy of Bevacizumab in Recurrence Metastatic Ovarian Cancer As a Second-Line and Beyond”. 2022. Latakia University Journal -Medical Sciences Series 44 (1): 49-57. https://journal.latakia-univ.edu.sy/index.php/hlthscnc/article/view/12000.